All In Biotech

Drug Trial Radar · NCT06740474

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

A Phase 1a, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-6250 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 31, 2025

Primary completion

Jul 8, 2025

Study completion Jul 8, 2025

Sponsor

Lead sponsor
Assembly BiosciencesIndustry
Sponsor type
Industry
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess safety, tolerability, and pharmacokinetics of single ascending doses (SAD) and multiple-ascending doses (MAD) of ABI-6250 in healthy participants. Effect of food will also be evaluated in Part A.

Conditions

  • Hepatitis Delta Virus
  • Hepatitis D

Interventions

  • ABI-6250Drug

    Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

  • PlaceboDrug

    Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with AEs, premature treatment discontinuation due to AEs and abnormal laboratory resultsTime frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  2. Area Under the Plasma Concentration Time Curve (AUC) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  3. Maximum Observed Plasma Concentration (Cmax) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  4. Time to Cmax (Tmax) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  5. Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  6. Apparent Systemic Clearance (CL/F) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  7. Apparent Volume of Distribution (Vz/F) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
  8. Dose normalized AUCs and Cmax of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.